Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/128139
Title: Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe
Author: Mansfeld, M.
Skrahina, A.
Shepherd, L.
Schultze, A.
Panteleev, A. M.
Miller, R. F.
Miró Meda, José M.
Zeltina. I.
Tetradov, S.
Furrer, H.
Kirk, O.
Grzeszczuk, A.
Bolokadze, N.
Matteelli, A.
Post, F. A.
Lundgreen, J. D.
Mocroft, A.
Efsen, A. M. W.
Podlekareva, D. N.
González Martín, Julián
Tudó i Vilanova, Griselda
Alcaide Fernández de Vega, Fernando
TB:HIV study group in EuroCoord
Keywords: Infeccions per VIH
Tuberculosi
HIV infections
Tuberculosis
Issue Date: 11-May-2015
Publisher: Wiley
Abstract: Objectives: The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences between treatment centres in Eastern (EE) and Western Europe (WE). Methods: Thirty‐eight European HIV and TB treatment centres participating in the TB:HIV study within EuroCoord completed a survey on health care management for coinfected patients in 2013 (EE: 17 respondents; WE:21; 76% of all TB:HIV centres). Descriptive statistics were obtained for regional comparisons. The reported data on health care strategies were compared with actual clinical practice at patient level via data derived from the TB:HIV study. Results: Respondent centres in EE comprised: Belarus (n = 3), Estonia (1), Georgia (1), Latvia (1), Lithuania (1), Poland (4), Romania (1), the Russian Federation (4) and Ukraine (1); those in WE comprised: Belgium (1), Denmark (1), France (1), Italy (7), Spain (2), Switzerland (1) and UK (8). Compared with WE, treatment of HIV and TB in EE are less often located at the same site (47% in EE versus 100% in WE; P < 0.001) and less often provided by the same doctors (41% versus 90%, respectively; P = 0.002), whereas regular screening of HIV‐infected patients for TB (80% versus 40%, respectively; P = 0.037) and directly observed treatment (88% versus 20%, respectively; P < 0.001) were more common in EE. The reported availability of rifabutin and second‐ and third‐line anti‐TB drugs was lower, and opioid substitution therapy (OST) was available at fewer centres in EE compared with WE (53% versus 100%, respectively; P < 0.001). Conclusions: Major differences exist between EE and WE in relation to the organization and delivery of health care for HIV/TB‐coinfected patients and the availability of anti‐TB drugs and OST. Significant discrepancies between reported and actual clinical practices were found in EE.
Note: Versió postprint del document publicat a: https://doi.org/10.1111/hiv.12256
It is part of: HIV Medicine, 2015, vol. 16, num. 9, p. 544-552
Related resource: https://doi.org/10.1111/hiv.12256
URI: http://hdl.handle.net/2445/128139
ISSN: 1464-2662
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
655731.pdf373.17 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.